AGTC is developing rAAV2tYF-PR1.7-hCNGB3, a recombinant adeno-associated virus (rAAV) vector expressing the human CNGB3 gene, for treatment of achromatopsia, an inherited retinal disorder characterized by markedly reduced visual acuity, extreme light sensitivity and absence of color discrimination [1]. We report here results of a study evaluating the safety and biodistribution of rAAV2tYF-PR1.7-hCNGB3 in cynomolgus macaques. Results of this study have recently been published [2].
 The rAAV2tYF-PR1.7-hCNGB3 vector was manufactured using a recombinant herpes simplex virus (rHSV) complementation system in suspension-cultured baby hamster kidney (sBHK) cells [3] , clarified by filtration, purified by affinity chromatography followed by cation-exchange chromatography and formulated in balanced salt solution (BSS) containing 0.014% Tween 20.  Three groups of animals (n=2 males and 2 females per group) received a subretinal injection in one eye of 300 µL containing either vehicle or rAAV2tYF-PR1.7-hCNGB3 at one of two concentrations (4 × 10 11 or 4 × 10 12 vg/mL) and were evaluated for safety and biodistribution over a 3-month period prior to euthanasia. Animals were administered test article or vehicle control in the right eye via subretinal injection on Study Day 1 at a volume of 300 mL per eye (2 × 150 µL injections). The left eye was not treated. Study design is shown in Table 1 .  Toxicity assessment was based on mortality, clinical observations, body weights, ophthalmic examinations, intraocular pressure (IOP) measurements, electroretinography (ERG), visual evoked potentials (VEP), and clinical and anatomic pathology.  Vector shedding and biodistribution was assessed by qPCR analyses. Immune responses to AAV and hCNGB3
were measured by ELISA, Elispot, or neutralization antibody assay for AAV2tYF. 
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RESULTS
 There were no test article-related effects on intraocular pressure, visual evoked potential responses, hematology or clinical chemistry parameters, or gross necropsy observations.  Biodistribution studies demonstrated that the vector did not spread widely or consistently outside the injected eye. High levels of vector DNA were found in vector-injected eyes but minimal or no vector DNA was found in any other tissue (Tables 2 & 3) .  Serum anti-AAV antibodies developed in all vector-injected animals (Table 4) 
